Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04020510 · ClinicalTrials.gov registry record · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
A Phase 4 study of Overactive Bladder, sponsored by Walter Reed National Military Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 184
- Enrollment target
- 1
- Study location
NCT04020510: Recruiting Phase 4 study of Overactive Bladder, sponsored by Walter Reed National Military Medical Center.
NCT04020510 is a Phase 4 study of Overactive Bladder that is actively recruiting participants, run by Walter Reed National Military Medical Center. The registered enrollment target is 184 participants, roughly in line with the 203-participant average among 46 other Overactive Bladder trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04020510, a Phase 4 study of Overactive Bladder, is actively recruiting participants, sponsored by Walter Reed National Military Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 184 participants
- Enrollment target
- 1
- Study location
Study Summary
OnabotulinumtoxinA is an effective treatment for both idiopathic and neurogenic overactive bladder and was FDA approved for this indication in 2013. The standard technique for injecting onabotulinumtoxinA into the detrusor is mixing 100 units of onabotulinumtoxinA into 10mL of injectable normal saline and injecting 20 sites with 0.5mL in the posterior wall of hte bladder for idiopathic overactive bladder and mixing 200 units into 30mL and injecting 30 sites with 1mL for neurogenic overactive bladder. The purpose of this study is to compare the efficacy of a technique using a reduced number of injections with the same dosage of onabotulinumtoxinA to the standard technique. The hypothesis is that the reduced technique will not be inferior in terms of efficacy as the standard technique and that there will be a lower incidence of urinary tract infections and urinary retention requiring catheterization post-procedure.
Primary Outcome
The overactive bladder questionnaire short form is a validated questionnaire assessing both symptoms and quality of life related to overactive bladder. The survey has two subscales, a health related quality of life scale and a symptom severity scale. Each subscale is scored separately with a range of 0 to 100. For health related quality of life a score of 0 indicates worst quality of life and 100 indicating best quality of life. For symptom severity, the scores also range from 0 to 100 but with
Conditions Studied
Interventions
- DRUG onaBoNT-A
Study Locations (1)
Maryland
- Walter Reed National Military Medical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2021-12-31 |
| Phase | Phase 4 |
What NCT04020510 shows while recruiting
NCT04020510 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 203-participant average among 46 other Overactive Bladder trials with a reported enrollment target.
The record links to 1 condition, with Overactive Bladder appearing as the primary indexed condition, and to 1 intervention - of which onaBoNT-A is the first listed.
NCT04020510 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04020510 about?
NCT04020510 is a clinical study titled "Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder". OnabotulinumtoxinA is an effective treatment for both idiopathic and neurogenic overactive bladder and was FDA approved for this indication in 2013. The standard technique for injecting onabotulinumtoxinA into the detrusor is mixing 100 units of onabotulinumtoxinA into 10mL of injectable normal sali...
What is the current status of trial NCT04020510?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 184 participants. The study started on 2019-07-01. Estimated completion is 2021-12-31.
What conditions does trial NCT04020510 study?
This clinical trial studies the following conditions: Overactive Bladder.
What interventions are being tested in trial NCT04020510?
The interventions under investigation include: onaBoNT-A (DRUG).
Who is sponsoring clinical trial NCT04020510?
This trial is sponsored by Walter Reed National Military Medical Center, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04020510 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overactive Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04020510's enrollment target sits among peer trials
184 16th of 46 higher than 31 of 46 other Overactive Bladder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Overactive Bladder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bladder Botox UTI Antibiotic Prophylaxis
RECRUITING · Phase 4
-
Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks
RECRUITING · Phase 4
-
TReating Incontinence for Underlying Mental and Physical Health
RECRUITING · Phase 4
-
Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder
COMPLETED · Phase 4
-
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
COMPLETED · Phase 4
-
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
- NCT04700332 · 184 participants · Phase 2
PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI